QUININE SULFATE CAPSULES 200MG 200 MG
QUININE SULFATE : 200 MG · DIN 00093742 · D.C. LABS LIMITED
Health Canada status: CANCELLED POST MARKET
What is QUININE SULFATE CAPSULES 200MG?
QUININE SULFATE CAPSULES 200MG 200 MG contains QUININE SULFATE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 00093742, held by D.C. LABS LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 23-Apr-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00093742 |
|---|---|
| Brand name | QUININE SULFATE CAPSULES 200MG |
| Generic / active ingredient | QUININE SULFATE : 200 MG |
| Manufacturer | D.C. LABS LIMITED |
| Strength | 200 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | P01BC01 QUININE |
| AHFS class | 08:30.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 23-Apr-2002 |
| Original market date | 1951-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code P01BC01 QUININE. 4 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PRO-QUININE - 200 | 200 MG | CAPSULE | PRO DOC LIMITEE | MARKETED | DIN 02311216 |
| PRO-QUININE - 300 | 300 MG | CAPSULE | PRO DOC LIMITEE | MARKETED | DIN 02311224 |
| TEVA-QUININE | 200 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00021008 |
| TEVA-QUININE | 300 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00021016 |
| APO-QUININE | 200 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02254514 |
| APO-QUININE | 300 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02254522 |
| JAMP-QUININE | 200 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02445190 |
| JAMP-QUININE | 300 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02445204 |
| QUININE - ODAN | 200 MG | CAPSULE | ODAN LABORATORIES LTD | DORMANT | DIN 00695440 |
| QUININE - ODAN | 300 MG | CAPSULE | ODAN LABORATORIES LTD | DORMANT | DIN 00695459 |
Who else supplies QUININE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. QUININE appears in 4 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.